posted on 2012-06-27, 00:00authored byJ. Lee Villano, Nathalie Letarte, Linda R. Bressler
The benefit of six cycles of adjuvant temozolomide was documented in a
randomized phase III (EORTC‐NCIC CE.3) trial and this therapy, following combined
temozolomide and radiation, is the standard of care for patients with newly
diagnosed glioblastoma. We comment on the differences on length of adjuvant
therapy in both clinical practice and national studies (e.g. RTOG 0825), usually
doubling the length than in the EORTC/NCIC study, and relate to historic adjuvant
trials for solid tumors.